Dewpoint Therapeutics has entered a strategic partnership with Evotec to progress the research and development of its oncology pipeline programmes comprising condensate modifying therapeutics (c-mods).
The c-mods will be advanced to the investigational new drug application (IND) stage leveraging INDiGO, a wholly integrated data-driven platform of Evotec.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Dewpoint’s oncology pipeline programmes were discovered using its condensate biology and artificial intelligence technology platform to detect biomolecular condensate modulators.
C-mods could offer new treatment options for complex ailments and targets that were previously undruggable.
Using Evotec’s expertise, the pre-clinical development candidates in Dewpoint’s pipeline will be de-risked and expedited to clinical trials in humans.
The deal will facilitate Dewpoint in expanding its capital efficiency while reducing risks.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataDewpoint’s agreement is based on a risk-sharing approach under which Evotec is entitled to receive milestone and royalty payments contingent on the programmes’ success.
Dewpoint Therapeutics CEO Ameet Nathwani stated: “Dewpoint’s strategic partnership with Evotec leverages the world-class speed of their development platform to accelerate our oncology assets into the clinic.
“Evotec’s integrated state-of-the-art operational technologies have been proven to deliver high-quality INDs across the industry.
“A strategic relationship of this nature significantly enhances our development capabilities which can be transformative for a company at our stage of development, and we are delighted to have been able to forge this partnership with a leader like Evotec.”
In September 2023, Dewpoint and Chemify partnered to accelerate the discovery of molecules to treat cancer and neurodegeneration.
